{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:44:38Z","timestamp":1792683878839,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Idecabtagene vicleucel (ide-cel) is a B-cell-maturation antigen (BCMA)-directed chimeric antigen receptor T cell therapy. We performed a post hoc analysis of a single-arm phase 1 multicenter study in relapsed\/refractory multiple myeloma (CRB-401) (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200962; median follow-up, 18.1 months). The primary endpoint was safety outcomes, and secondary endpoints included overall response rate (ORR), complete response (CR) and very good partial response (VGPR). The study met its primary endpoint with low rates of grade 3\/grade 4 cytokine release syndrome (6.5%) and neurotoxicity (1.6%). ORR was 75.8%; 64.5% achieved VGPR or better and 38.7% achieved CR or stringent CR. Among exploratory endpoints, median duration of response, progression-free survival (PFS) and overall survival were 10.3, 8.8 and 34.2 months, respectively, and ide-cel expansion in blood and bone marrow correlated with clinical efficacy and postinfusion reduction of soluble BCMA. Patients with PFS\u2009\u2265\u200918 months had more naive and less exhausted T cells in apheresis material and improved functional T cell phenotype in the drug product compared with those with less durable responses. These results confirm ide-cel safety, tolerability and efficacy and describe T cell qualities that correlate with durable response. Clinicaltrials.gov identifier :\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02658929\" ext-link-type=\"uri\">NCT02658929<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-023-02496-0","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T12:01:34Z","timestamp":1692273694000},"page":"2286-2294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":128,"title":["Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur S.","family":"Raje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-0376","authenticated-orcid":false,"given":"Jes\u00fas G.","family":"Berdeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3604-2574","authenticated-orcid":false,"given":"David S.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepu","family":"Madduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacalyn","family":"Rosenblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":false,"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Massaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Petrocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Yeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Finney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Caia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy B.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Rytlewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaymes","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Hege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7344-9795","authenticated-orcid":false,"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4362-9875","authenticated-orcid":false,"given":"James N.","family":"Kochenderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"2496_CR1","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.clml.2019.10.002","volume":"20","author":"S Jagannath","year":"2020","unstructured":"Jagannath, S. et al. Treatment journeys of patients with newly diagnosed multiple myeloma (NDMM): results from the Connect MM Registry. Clin. Lymphoma Myeloma Leuk. 20, 272\u2013276 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"2496_CR2","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Primers 3, 17046 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2496_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar, S. V. & Kumar, S. Multiple myeloma: diagnosis and treatment. Mayo Clin. Proc. 91, 101\u2013119 (2016).","journal-title":"Mayo Clin. Proc."},{"key":"2496_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","volume":"78","author":"IS Nijhof","year":"2018","unstructured":"Nijhof, I. S., van de Donk, N., Zweegman, S. & Lokhorst, H. M. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs 78, 19\u201337 (2018).","journal-title":"Drugs"},{"key":"2496_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00507-2","volume":"11","author":"S Jagannath","year":"2021","unstructured":"Jagannath, S. et al. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer J. 11, 116 (2021).","journal-title":"Blood Cancer J."},{"key":"2496_CR6","unstructured":"Davies, F. et al. A systematic literature review to assess efficacy of treatments in triple-class exposed relapsed and refractory multiple myeloma patients. Poster EP1033. Proceedings of European Hematology Association (EHA) Virtual Congress (EHA Library, 2020)."},{"key":"2496_CR7","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi, U. H. et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 33, 2266\u20132275 (2019).","journal-title":"Leukemia"},{"key":"2496_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/cpt.1674","volume":"107","author":"SA Holstein","year":"2020","unstructured":"Holstein, S. A. & Lunning, M. A. CAR T-cell therapy in hematologic malignancies: a voyage in progress. Clin. Pharmacol. Ther. 107, 112\u2013122 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"key":"2496_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni, L. & Kochenderfer, J. N. CAR T cell therapies for patients with multiple myeloma. Nat. Rev. Clin. Oncol. 18, 71\u201384 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2496_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","volume":"15","author":"JN Brudno","year":"2018","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Chimeric antigen receptor T-cell therapies for lymphoma. Nat. Rev. Clin. Oncol. 15, 31\u201346 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2496_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"2496_CR12","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI125423","volume":"129","author":"OC Finney","year":"2019","unstructured":"Finney, O. C. et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J. Clin. Invest. 129, 2123\u20132132 (2019).","journal-title":"J. Clin. Invest."},{"key":"2496_CR13","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","volume":"9","author":"SF Cho","year":"2018","unstructured":"Cho, S. F., Anderson, K. C. & Tai, Y. T. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front. Immunol. 9, 1821 (2018).","journal-title":"Front. Immunol."},{"key":"2496_CR14","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","volume":"127","author":"YT Tai","year":"2016","unstructured":"Tai, Y. T. et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood 127, 3225\u20133236 (2016).","journal-title":"Blood"},{"key":"2496_CR15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","volume":"158","author":"E Sanchez","year":"2012","unstructured":"Sanchez, E. et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br. J. Haematol. 158, 727\u2013738 (2012).","journal-title":"Br. J. Haematol."},{"key":"2496_CR16","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter, R. O. et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19, 2048\u20132060 (2013).","journal-title":"Clin. Cancer Res."},{"key":"2496_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/hum.2018.001","volume":"29","author":"KM Friedman","year":"2018","unstructured":"Friedman, K. M. et al. Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells. Hum. Gene Ther. 29, 585\u2013601 (2018).","journal-title":"Hum. Gene Ther."},{"key":"2496_CR18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar, O. U. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44, 380\u2013390 (2016).","journal-title":"Immunity"},{"key":"2496_CR19","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2496_CR20","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin, T. et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin. Oncol. 41, 1265\u20131274 (2023).","journal-title":"J Clin. Oncol."},{"key":"2496_CR21","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2496_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur, M. K. et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat. Commun. 12, 868 (2021).","journal-title":"Nat. Commun."},{"key":"2496_CR23","doi-asserted-by":"crossref","unstructured":"Reyes, K. R., Liu, Y. C., Huang, C. Y. et al. Salvage therapies and clinical outcomes after relapse following BCMA CAR-T in patients with relapsed\/refractory multiple myeloma. Proc. 2022 Intern. Myeloma Soc. Annual Meeting and Exposition (2022).","DOI":"10.1016\/S2152-2650(22)00324-X"},{"key":"2496_CR24","unstructured":"Rodriguez-Otero, P., San-Miguel, J. F., Anderson, L. D. et al. Myeloma\/amyloidosis: therapy, excluding transplantation. Proc. 2021 American Soc. Hemat. Ann. Meeting and Exposition (2021)."},{"key":"2496_CR25","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839\u2013852 (2020).","journal-title":"Lancet"},{"key":"2496_CR26","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2496_CR27","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer, J. N. et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J. Clin. Oncol. 35, 1803\u20131813 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2496_CR28","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.3390\/cancers13174279","volume":"13","author":"S Lamure","year":"2021","unstructured":"Lamure, S. et al. Clinical and product features associated with outcome of DLBCL patients to CD19-targeted CAR T-cell therapy. Cancers (Basel) 13, 4279 (2021).","journal-title":"Cancers (Basel)"},{"key":"2496_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 20, 31\u201342 (2019).","journal-title":"Lancet Oncol."},{"key":"2496_CR30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188\u2013195 (2014).","journal-title":"Blood"},{"key":"2496_CR31","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar, S. V. et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117, 4691\u20134695 (2011).","journal-title":"Blood"},{"key":"2496_CR32","unstructured":"US Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry. https:\/\/www.fda.gov\/media\/71195\/download (2018)."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02496-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02496-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02496-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T07:17:51Z","timestamp":1783667871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02496-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2496"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02496-0","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,17]]},"assertion":[{"value":"28 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.L. received institutional grants and consulting fees from Bristol Myers Squibb, Kite-Gilead and Janssen; institutional grants only from 2Seventy Bio, Merck and Takeda; institutional consulting fees only from Novartis, CellMedica and Legend Biotech; and participated in a data safety monitoring or advisory board for Pfizer and Sorrento. NSR received consulting fees from Bristol Myers Squibb and research funding from 2Seventy Bio. J.G.B. reports institutional support from Bristol Myers Squibb during the conduct of the study; received institutional grants and consulting fees from bluebird bio, Celgene, Janssen, Takeda and CRISPR Therapeutics; received institutional grants only from 2Seventy Bio, Acetylon, CARsgen, Fate Therapeutics, GlaxoSmithKline, Incyte, Karyopharm, Novartis, Sanofi, Teva, AbbVie, Amgen, C4 Therapeutics, Cartesian, Celularity, EMD Sorono, Genentech, Icnos Sciences, Lilly, Poseida and Zentalis; and received institutional consulting fees only from Legend Biotech, Bristol Myers Squibb, Kite Pharma and Secura Bio. D.S.S. reports nonfinancial support from Bristol Myers Squibb during the conduct of the study and received consulting and personal fees from Bristol Myers Squibb for participation in advisory boards and speaker bureaus. S.J. received consulting fees from Bristol Myers Squibb, Janssen, Karyopharm, Legend Biotech, Sanofi and Takeda; participated in a Data Monitoring Committee; and has a leadership or fiduciary role at the International Myeloma Society, Society of Hematologic Oncology and American Society of Hematology. D.M. was an employee of Mount Sinai Medical Center, New York, at the time the work was conducted and received consulting\/advisory fees from Roivant, Takeda, Janssen Oncology, Celgene, Legend Biotech, GlaxoSmithKline and Foundation Medicine, but is now an employee of Janssen Oncology with stock and other ownership interests. M.L. reports consultant fees\/grants from Allogene, bluebird bio, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen Biotech, Karyopharm Therapeutics, Oncopeptides, Sanofi and Takeda. J.R. received grants from Celgene and Bristol Myers Squibb, consulting fees from Parexel, Imaging Endpoint, Bioclinica and Attivare Therapeutics, and participated in a data safety monitoring board for Karyopharm and advisory boards for Amgen, Bristol Myers Squibb, Merck, Kite Pharma, Partner TX, Celgene and Dava Oncology. M.V.M. received research funding from Kite Pharma and Novartis; royalties from Novartis; consulting fees from Adaptimmune, Agenus, Allogene, Arcellx, Astellas, AstraZeneca, Atara, Bayer, Bristol Myers Squibb, Cabaletta Bio, Cellectis, CRISPR Therapeutics, Genocea, In8bio, Intellia, GlaxoSmithKline, Kite Pharma, Micromedicine\/BendBio, Neximmune, Novartis, Oncternal, Sanofi, TCR2, Tmunity and WindMIL; payment for expert testimony from Australia FPA patent attorneys; participated in a data safety monitoring or advisory board for Adaptimmune, GlaxoSmithKline and Cabaletta Bio; has multiple patents not related to this work; holds stock or has stock options in 2Seventy Bio, Century Therapeutics, Genocea, Neximmune, Oncternal and TCR2; and is on the board of directors for 2Seventy Bio since the completion of this work. M.M., F.P., A.Y. and O.F. report employment at 2Seventy Bio\/bluebird bio. F.P. and O.F. also hold stocks in 2Seventy Bio\/bluebird bio. A.C., N.M., T.B.C., J.F. and J.R. report employment at Bristol Myers Squibb. Z.Y. and K.H. are former employees of Bristol Myers Squibb. Z.Y. is currently employed at Ascentage Pharma. Z.Y., N.M., T.B.C., J.F., J.R. and K.H. also hold stocks in Bristol Myers Squibb. K.H. also has a leadership or fiduciary role at Mersana Therapeutics, Graphite Bio and the Society for Immunotherapy of Cancer. J.R. also reports holding stock in Adaptive Biotechnologies. N.C.M. reports stock and other ownership interests from OncoPep, C4 Therapeutics and Raqia, and consulting fees from AbbVie, Adaptive Biotechnologies, Amgen, BeiGene, Bristol Myers Squibb, Bristol Myers Squibb\/Celgene, Janssen, OncoPep, Karyopharm Therapeutics, Legend Biotech, Novartis, RaqiaPatents, Sebia and Takeda; he is also the recipient of grants from the National Cancer Institute. J.N.K. is the principal investigator of a research agreement between Celgene, Bristol Myers Squibb and the National Cancer Institute that provided funding for this work and the principal investigator of a research agreement between Kite, a Gilead company, and the National Cancer Institute; received CAR T cells for this work from Celgene; has a patent for CARs targeting B-cell maturation agent used in this work for which he receives royalties; and has received royalties from Kite, a Gilead Company, and Kyverna for unrelated work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}